查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2068254

動脈粥狀硬化市場：策略性洞察與預測（2026-2031 年）

Atherosclerosis Market - Strategic Insights and Forecasts (2026-2031)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球動脈粥狀硬化市場預計在預測期內將以 3.0% 的複合年成長率成長，從 2026 年的 354 億美元成長到 2031 年的 411 億美元。

動脈粥狀硬化是一種慢性心血管疾病，其特徵是脂質、膽固醇、發炎細胞和纖維物質在動脈壁內積聚，導致斑塊形成和血流減少。該疾病是冠狀動脈疾病、中風、周邊動脈疾病和其他心血管併發症的主要潛在病因。由於心血管疾病仍然是全球主要的死亡原因之一，因此對有效的動脈粥狀硬化診斷、預防和治療方案的需求持續成長。肥胖、糖尿病、高血壓、吸煙和缺乏運動等因素的日益加重進一步加劇了疾病的盛行率上升和市場擴張。

藥物治療和精準心血管醫學的進步正在改變市場格局。儘管他汀類藥物仍然是動脈粥狀硬化治療的基礎，但諸如PCSK9抑制劑、抗發炎療法、基於RNA的降脂藥物以及聯合治療等新型治療方案正在拓展治療的可能性。這些創新使醫療專業人員能夠更好地管理膽固醇水平，並降低高風險患者群體的心血管風險。

人們對心血管疾病預防保健意識的不斷提高是推動市場成長的另一個關鍵因素。各國政府、醫療專業人員和公共衛生機構正加大對篩檢計畫、膽固醇監測計畫和生活方式改善宣傳活動的投入，以在嚴重發生前降低心血管風險因素。早期診斷和積極的疾病管理正成為醫療保健策略的核心要素。

技術創新也正在提升疾病管理能力。先進的影像技術、非侵入性診斷方法、人工智慧（AI）驅動的風險評估工具以及數位健康平台，正在改善動脈粥狀硬化性疾病的檢測和監測。這些進步使得早期介入和更個人化的治療方案成為可能，從而改善患者的長期預後。

此外，新興經濟體醫療保健支出不斷成長以及心血管疾病治療服務覆蓋範圍的擴大，進一步推動了市場發展。醫療基礎設施的改善、保險覆蓋範圍的擴大以及獲得專業心血管護理的機會增加，為全部區域的市場成長創造了有利環境。

北美目前佔據最大的區域市場佔有率，這主要得益於其心血管疾病的高發生率、先進的醫療保健體系、強勁的藥物創新能力以及廣泛的預防醫學。歐洲仍然是一個重要的市場，這得益於其完善的心血管治療方案和人口老化。亞太地區預計將成為成長最快的地區，這主要歸功於心血管疾病發病率的上升、醫療保健的現代化、醫療保健投資的增加以及人們對心血管健康的日益重視。

市場促進因素

動脈粥狀硬化市場的主要促進因素之一是全球心血管疾病盛行率的不斷上升。心肌梗塞、中風、周邊動脈疾病以及其他與動脈粥狀併發症相關的心血管併發症的發生率不斷攀升，導致人們對有效的治療和預防策略的需求持續成長。

人口老化是另一個主要的成長要素。老年人由於血管累積損傷和長期暴露於心血管危險因素，患動脈粥狀硬化性疾病的風險增加。隨著平均預期壽命的延長，需要長期心血管管理的患者人數也增加。

降脂療法的進步也顯著促進了市場成長。新型治療方法的研發超越了傳統的他汀類藥物，改善了高心血管風險和難治性高高膽固醇症患者的治療效果。

對預防醫學日益重視，進一步加速了市場擴張。醫療保健系統正著重強調早期診斷、膽固醇管理、戒菸、飲食療法和心血管風險降低計劃，以減輕疾病負擔和醫療成本。

新興國家醫療基礎設施的擴張也促進了市場成長。診斷服務、心血管專家和藥物治療的可近性提高，提高了治療率和疾病管理能力。

個人化醫療方法和先進診斷技術的日益普及，使臨床醫生能夠更有效地識別高風險患者並最佳化治療策略。

市場限制因素

儘管動脈粥狀硬化市場成長前景良好，但仍面臨許多挑戰。其中一個主要阻礙因素是競爭異常激烈的醫藥市場。學名藥的激增加劇了價格壓力，限制了品牌藥的成長機會。

專利到期和學名藥的競爭持續影響多個治療領域的盈利。隨著重磅心血管藥物壟斷地位的逐漸消退，藥廠面臨越來越大的壓力，需要使其新的治療方案脫穎而出。

治療依從性仍然是一項關鍵挑戰。動脈粥狀硬化的治療通常需要終身服藥、生活方式調整和定期監測。患者依從性差會導致治療效果降低，增加心血管不利事件的風險。

一些創新治療方法價格昂貴，這可能會限制其在某些醫療保健計劃下的普及。尤其是在發展中地區，人們可能會擔心先進生物製藥和特殊心血管治療的保險報銷問題以及由此帶來的經濟負擔。

心血管疾病診斷延誤仍是一大障礙。許多患者在病情發展到晚期之前都無症狀，導致錯失早期療育和預防性治療的機會。

心血管藥物的核准和長期安全性評估的監管要求也可能導致製藥公司研發週期延長和成本增加。

對技術和細分市場的洞察

依藥物類別分類，市場可分為他汀類藥物、血管收縮素受體阻斷劑（ARB）、血管收縮素轉化酵素（ACE）抑制劑、鈣離子通道阻斷劑、利尿劑和其他心血管治療藥物。他汀類藥物因其在降低膽固醇和控制心血管風險方面的顯著作用，繼續佔據市場主導地位。

就治療方法而言，藥物治療佔據最大的市場佔有率。這是因為藥物治療仍然是大多數患者族群治療動脈粥狀硬化的基礎。介入治療方法和器械主要用於疾病進展期的病例。

診斷方法、影像技術、多普勒超音波、踝臂指數 (ABI) 測試、心電圖、心臟超音波圖、血液生物標記分析和先進的心血管篩檢技術在疾病檢測和監測中發揮著至關重要的作用。

就治療環境而言，具備全面心血管照護能力的醫院佔據了大部分市場佔有率。專科心血管診所、門診中心和居家醫療服務也為疾病管理做出了重要貢獻。

人工智慧診斷、預測分析、數位療法、穿戴式監測設備和精準醫療平台等新興技術有望進一步改善疾病管理和患者預後。

競爭格局與策略展望

動脈粥狀硬化治療市場的競爭格局以持續的藥物創新、策略聯盟以及對心血管研究投入的不斷增加為特徵。領先企業致力於開發新一代降血脂療法、抗發炎療法和精準醫療解決方案，旨在改善心血管疾病的治療效果。

各機構正大力投資研發，以滿足尚未滿足的需求，特別是那些無法透過傳統治療方法獲得最佳治療效果的患者的需求。預計新型藥物和聯合治療將在未來的市場成長中發揮越來越重要的作用。

製藥公司、生物技術公司、學術機構和醫療機構之間的策略夥伴關係正在推動創新並加速臨床開發專案。這些夥伴關係正在推動生物標記的發現、治療方法的進步和商業化進程。

此外，該市場對數位健康技術和遠端醫療平台的採用率正在不斷提高。遠端監測、病人參與應用程式以及數據驅動的心血管疾病管理項目，都有助於提高治療依從性，並加強長期疾病管理。

由於醫療基礎設施的不斷改善、心血管疾病盛行率的上升以及治療服務可近性的提高，新興市場預計將帶來巨大的成長機會。亞太地區和拉丁美洲國家預計將為未來的市場擴張做出重大貢獻。

未來的競爭預計將集中在治療效果、安全性、可負擔性、患者用藥依從性和個人化治療策略等。能夠提供創新且經濟高效的心血管解決方案的公司有望鞏固其長期市場地位。

結論

由於心血管疾病仍然是全球醫療保健領域的重大負擔，動脈粥狀硬化市場預計將持續成長。疾病盛行率上升、人口老化、預防性醫療保健工作的不斷加強以及心血管治療領域的持續創新，都為該市場的長期發展提供了支持。

儘管學名藥競爭、治療依從性、成本負擔和監管複雜性等挑戰依然存在，但降血脂療法、精準醫療、數位健康技術和早期診斷能力的持續進步預計將推動市場擴張。隨著心血管疾病的預防和管理在醫療保健系統中日益受到重視，動脈粥狀硬化市場將繼續成為全球心血管醫療保健產業的重要組成部分。

本報告的主要特點

  • 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業部門進行詳細的市場洞察。
  • 競爭格局：我們了解主要參與者的策略舉措，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策以開發新的收入來源。
  • 適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

調查範圍

  • 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期間為 2026 年至 2031 年。
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭對手定位、策略、市場佔有率評估和貿易分析
  • 細分市場和區域銷售成長及預測評估
  • 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

  • 市場概述
  • 主要需求因素
  • 策略市場變化
  • 治療和介入措施的變化
  • 各區域需求概覽
  • 競爭格局概述
  • 未來展望與產業轉型

第2章 疾病與流行病學分析

  • 動脈粥狀硬化概述
  • 病理學和斑塊形成
  • 疾病進展與臨床負擔
  • 流行病學分析
    • 全球盛行率和發病率
    • 按年齡分類的疾病負擔
    • 性別趨勢
    • 死亡率和發病率趨勢
  • 風險因素分析
    • 高血壓
    • 高血脂症
    • 糖尿病
    • 肥胖
    • 吸煙和久坐的生活方式
    • 慢性腎臟病
  • 疾病亞型分析
    • 冠狀動脈粥狀硬化
    • 頸動脈粥狀硬化
    • 周邊動脈粥狀硬化
    • 主動脈粥狀硬化
  • 診斷過程和篩檢趨勢
  • 未滿足的臨床需求

第3章 市場動態

  • 市場促進因素
    • 心血管疾病負擔加重
    • 廣泛採用降血脂療法
    • 微創血管介入治療的擴展
    • 擴大人工智慧驅動的心血管診斷的應用
  • 市場限制因素
    • 先進生物製藥高成本
    • 限制心血管疾病預防篩檢的途徑
    • 嚴格的規章制度和績效檢驗要求
  • 市場機遇
    • PCSK9抑制劑和新型脂質療法的擴展
    • 數位心血管監測的發展
    • 對個人化心血管風險管理的新需求
    • 拓展新興醫療保健市場
  • 供應鏈分析
  • 定價和兌換趨勢
  • 對醫療保健基礎設施的影響

第4章 商業和市場進入

  • 商業化框架
  • 目前還款狀態
  • 市場准入面臨的挑戰
  • 支付機構和醫院的採購趨勢
  • 預防性循環系統醫學計劃的作用
  • 患者對藥物的依從性和長期治療的持續性

第5章：創新與通路的現狀

  • 動脈粥狀硬化治療創新趨勢
  • 降血脂療法的演變
  • 管道現狀概述
  • 按臨床階段分類的管線候選藥物
    • 一期臨床試驗候選藥物
    • 二期臨床試驗候選藥物
    • 三期臨床試驗候選藥物
  • 作用機制分析
    • PCSK9抑制劑
    • 利用siRNA進行脂質治療方法
    • 抗發炎心血管藥物
    • CETP抑制劑
    • 基因編輯和基於RNA的治療方法
  • 血管影像和診斷領域的創新
  • 人工智慧和預測性心血管分析

第6章 當前治療狀況

  • 目前的標準治療
  • 藥物治療現狀
    • 他汀類藥物
    • PCSK9抑制劑
    • 抗血小板藥物
    • 抗凝血物
    • 抗高血壓治療
    • 抗發炎治療
  • 介入治療的現狀
    • 冠狀動脈支架置入術
    • 周邊血管介入治療
    • 頸動脈置入術
    • 動脈粥狀硬化斑塊切除術系統
  • 診斷和監測技術
  • 生活方式和預防管理方法

第7章：全球動脈硬化市場規模及預測

  • 全球市場概覽
  • 過往市場分析
  • 預測分析
  • 按治療方法分類的市場預測
  • 按藥物類別分類的市場預測
  • 按應用領域分類的市場預測
  • 區域市場預測

第8章：全球動脈硬化市場細分

  • 按治療類型
    • 藥物治療
    • 藥物釋放型支架
    • 動脈粥狀硬化斑塊切除術裝置
    • 血管影像系統
    • 數位心血管監測平台
  • 藥物類別
    • 他汀類藥物
    • PCSK9抑制劑
    • 抗血小板藥物
    • 抗凝血物
    • 抗高血壓藥物
    • 抗發炎治療
    • 其他
  • 適應症
    • 缺血性心臟疾病
    • 頸動脈疾病
    • 周邊動脈疾病
    • 主動脈粥狀硬化
    • 慢性完全閉塞

第9章 區域分析

  • 北美洲
    • 市場規模和成長趨勢
    • 心血管疾病負擔
    • 法規環境
    • 競爭強度
    • 技術採納趨勢
  • 歐洲
    • 市場規模和成長趨勢
    • 預防性心血管醫學簡介
    • 法規環境
    • 競爭強度
    • 贖回趨勢
  • 亞太地區
    • 市場規模和成長趨勢
    • 代謝性疾病負擔加重
    • 法規環境
    • 競爭強度
    • 醫療基礎設施擴建
  • 拉丁美洲
    • 市場規模和成長趨勢
    • 心血管疾病篩檢趨勢
    • 法規環境
    • 競爭強度
    • 訪問挑戰
  • 中東和非洲
    • 市場規模和成長趨勢
    • 慢性病的負擔
    • 法規環境
    • 競爭強度
    • 基礎設施現代化

第10章 主要國家分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 巴西
  • 墨西哥
  • 沙烏地阿拉伯
  • 南非

第11章 法規與政策概述

  • 美國法律規範
    • FDA醫藥品認證過程
    • 心血管醫療設備上市前核准 (PMA) 和 510(k)核准途徑
    • 上市後心血管監測
  • 歐洲法規結構
    • EMA藥物審查流程
    • 符合歐盟醫療器材法規
    • 心血管結局監測
  • 日本的法律規範
    • PMDA對心血管藥物的批准
    • 醫療設備的長期安全性評估
  • 印度的法律規範
    • CDSCO關於藥品和醫療設備的法規
    • 藥物安全監測要求
  • 中國的法律規範
    • 國家藥品管理局（NMPA）核准流程
    • 當地臨床檢驗要求
  • 全球兌換與HTA趨勢
  • 法規對創新的影響

第12章 競爭格局

  • 市場競爭概覽
  • 戰略定位分析
  • 產品系列基準測試
  • 夥伴關係關係的發展趨勢
  • 併購
  • 創新與產品線之間的競爭
  • 人工智慧和數位技術在心血管醫學領域融合的趨勢

第13章：公司簡介

  • Amgen
  • Novartis
  • Sanofi
  • Regeneron Pharmaceuticals
  • Abbott Laboratories
  • Boston Scientific
  • Medtronic
  • Philips
  • Terumo Corporation
  • BD

第14章：未來展望

  • 心血管疾病預防醫學的發展
  • 基於RNA的療法和基因療法的未來
  • 人工智慧驅動的心血管風險預測
  • 個人化血脂管理的未來
  • 新型介入技術
  • 長期戰略產業展望

第15章：調查方法

  • 調查方法概述
  • 資料收集框架
  • 首次調查的調查方法
  • 二手調查資料
  • 預測的前提條件
  • 數據檢驗和三角測量
  • 監管和臨床試驗數據來源的驗證。
  • 研究的限制和範圍
簡介目錄
Product Code: KSI-008714

The Global Atherosclerosis market is projected to grow at a CAGR of 3.0% over the forecast period, increasing from USD 35.4 billion in 2026 to USD 41.1 billion by 2031.

Atherosclerosis is a chronic cardiovascular condition characterized by the accumulation of lipids, cholesterol, inflammatory cells, and fibrous material within arterial walls, leading to plaque formation and reduced blood flow. The disease is a major underlying cause of coronary artery disease, stroke, peripheral artery disease, and other cardiovascular complications. As cardiovascular diseases remain among the leading causes of mortality worldwide, the demand for effective atherosclerosis diagnosis, prevention, and treatment solutions continues to increase. The growing burden of obesity, diabetes, hypertension, smoking, and sedentary lifestyles is further contributing to disease prevalence and market expansion.

The market is undergoing significant transformation due to advancements in pharmacological therapies and precision cardiovascular medicine. Statins continue to serve as the cornerstone of atherosclerosis management, while newer treatment options such as PCSK9 inhibitors, anti-inflammatory therapies, RNA-based lipid-lowering agents, and combination treatment regimens are expanding therapeutic possibilities. These innovations are helping healthcare providers achieve improved cholesterol control and cardiovascular risk reduction among high-risk patient populations.

Increasing awareness regarding preventive cardiovascular care is another important factor supporting market growth. Governments, healthcare providers, and public health organizations are investing in screening programs, cholesterol monitoring initiatives, and lifestyle modification campaigns to reduce cardiovascular risk factors before the onset of severe disease. Early diagnosis and proactive disease management are becoming central components of cardiovascular healthcare strategies.

Technological innovation is also enhancing disease management capabilities. Advanced imaging technologies, non-invasive diagnostic techniques, artificial intelligence-assisted risk assessment tools, and digital health platforms are improving the detection and monitoring of atherosclerotic disease. These developments enable earlier intervention and more personalized treatment approaches, supporting better long-term patient outcomes.

The market is further benefiting from increased healthcare expenditure and expanding access to cardiovascular treatment services in emerging economies. Improvements in healthcare infrastructure, insurance coverage, and access to specialty cardiovascular care are creating favorable conditions for market growth across developing regions.

North America currently represents the largest regional market due to high cardiovascular disease prevalence, advanced healthcare systems, strong pharmaceutical innovation, and widespread adoption of preventive care. Europe remains a significant market supported by established cardiovascular treatment programs and aging demographics. Asia Pacific is expected to witness the fastest growth due to rising cardiovascular disease incidence, healthcare modernization, increasing healthcare investments, and growing awareness of cardiovascular health.

Market Drivers

One of the primary drivers of the atherosclerosis market is the increasing prevalence of cardiovascular diseases globally. Rising rates of heart attacks, strokes, peripheral artery disease, and other cardiovascular complications associated with atherosclerosis are creating sustained demand for effective treatment and prevention strategies.

The growing aging population is another major growth driver. Older adults are at greater risk of developing atherosclerotic disease due to cumulative vascular damage and prolonged exposure to cardiovascular risk factors. Increasing life expectancy is expanding the patient population requiring long-term cardiovascular management.

Advancements in lipid-lowering therapies are significantly supporting market growth. The development of novel therapies beyond traditional statins is improving treatment outcomes for patients with elevated cardiovascular risk and treatment-resistant hypercholesterolemia.

The increasing emphasis on preventive healthcare is further accelerating market expansion. Healthcare systems are focusing on early diagnosis, cholesterol management, smoking cessation, dietary interventions, and cardiovascular risk reduction programs to reduce disease burden and healthcare costs.

Expansion of healthcare infrastructure in emerging economies is also contributing to market growth. Improved access to diagnostic services, cardiovascular specialists, and pharmaceutical therapies is increasing treatment rates and disease management capabilities.

Rising adoption of personalized medicine approaches and advanced diagnostic technologies is helping clinicians identify high-risk patients more effectively and optimize treatment strategies.

Market Restraints

Despite favorable growth prospects, the atherosclerosis market faces several challenges. One major restraint is the highly competitive nature of the pharmaceutical market. The widespread availability of generic cardiovascular drugs creates pricing pressure and limits revenue growth opportunities for branded therapies.

Patent expirations and generic competition continue to affect profitability across several therapeutic categories. As blockbuster cardiovascular drugs lose exclusivity, manufacturers face increasing pressure to differentiate newer treatment options.

Treatment adherence remains an important challenge. Atherosclerosis often requires lifelong therapy, lifestyle modifications, and regular monitoring. Poor patient compliance can reduce treatment effectiveness and increase the risk of adverse cardiovascular events.

The high cost of some innovative therapies may limit accessibility in certain healthcare systems. Advanced biologics and specialty cardiovascular treatments may create reimbursement challenges and affordability concerns, particularly in developing regions.

Late diagnosis of cardiovascular disease remains another obstacle. Many patients remain asymptomatic until advanced disease develops, reducing opportunities for early intervention and preventive management.

Regulatory requirements for cardiovascular drug approval and long-term safety evaluation can also increase development timelines and costs for pharmaceutical companies.

Technology and Segment Insights

The market can be segmented by drug class into statins, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics, and other cardiovascular therapies. Statins continue to dominate the market due to their established role in cholesterol reduction and cardiovascular risk management.

By therapy type, drug therapy accounts for the largest market share because pharmacological treatment remains the foundation of atherosclerosis management across most patient populations. Interventional procedures and device-based therapies are primarily utilized in advanced disease cases.

Based on diagnosis, imaging technologies, Doppler ultrasound, ankle-brachial index testing, electrocardiography, echocardiography, blood biomarker analysis, and advanced cardiovascular screening techniques play important roles in disease detection and monitoring.

By treatment setting, hospitals account for a substantial market share due to their comprehensive cardiovascular care capabilities. Specialty cardiovascular clinics, ambulatory care centers, and home healthcare services also contribute significantly to disease management.

Emerging technologies such as artificial intelligence-assisted diagnostics, predictive analytics, digital therapeutics, wearable monitoring devices, and precision medicine platforms are expected to further enhance disease management and patient outcomes.

Competitive and Strategic Outlook

The competitive landscape of the atherosclerosis market is characterized by ongoing pharmaceutical innovation, strategic partnerships, and increasing investment in cardiovascular research. Major companies are focusing on the development of next-generation lipid-lowering therapies, anti-inflammatory treatments, and precision medicine solutions aimed at improving cardiovascular outcomes.

Organizations are investing heavily in research and development to address unmet clinical needs, particularly among patients who do not achieve optimal outcomes with traditional therapies. Novel drug classes and combination treatment approaches are expected to play increasingly important roles in future market growth.

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and healthcare organizations are supporting innovation and accelerating clinical development programs. These partnerships facilitate biomarker discovery, therapeutic advancement, and commercialization efforts.

The market is also witnessing increased adoption of digital health technologies and telemedicine platforms. Remote monitoring, patient engagement applications, and data-driven cardiovascular management programs are helping improve treatment adherence and long-term disease control.

Emerging markets represent significant growth opportunities due to expanding healthcare infrastructure, increasing cardiovascular disease prevalence, and improving access to treatment services. Countries across Asia Pacific and Latin America are expected to contribute substantially to future market expansion.

Future competition is expected to focus on therapeutic efficacy, safety profiles, affordability, patient adherence, and personalized treatment strategies. Companies capable of delivering innovative and cost-effective cardiovascular solutions may strengthen their long-term market positions.

Conclusion

The atherosclerosis market is expected to experience sustained growth as cardiovascular diseases continue to represent a major global healthcare burden. Rising disease prevalence, increasing aging populations, expanding preventive healthcare initiatives, and ongoing innovation in cardiovascular therapeutics are supporting long-term market development.

Although challenges related to generic competition, treatment adherence, healthcare affordability, and regulatory complexity remain, continued advancements in lipid-lowering therapies, precision medicine, digital health technologies, and early diagnostic capabilities are expected to strengthen market expansion. As healthcare systems increasingly prioritize cardiovascular disease prevention and management, the atherosclerosis market will remain a critical component of the global cardiovascular healthcare industry.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Demand Drivers
  • 1.3 Strategic Market Shift
  • 1.4 Therapeutic and Interventional Evolution
  • 1.5 Regional Demand Overview
  • 1.6 Competitive Landscape Snapshot
  • 1.7 Future Outlook and Industry Transformation

2. Disease & Epidemiology Analysis

  • 2.1 Overview of Atherosclerosis
  • 2.2 Pathophysiology and Plaque Development
  • 2.3 Disease Progression and Clinical Burden
  • 2.4 Epidemiology Analysis
    • 2.4.1 Global Prevalence and Incidence
    • 2.4.2 Age-Wise Disease Burden
    • 2.4.3 Gender-Based Trends
    • 2.4.4 Mortality and Morbidity Trends
  • 2.5 Risk Factor Analysis
    • 2.5.1 Hypertension
    • 2.5.2 Hyperlipidemia
    • 2.5.3 Diabetes Mellitus
    • 2.5.4 Obesity
    • 2.5.5 Smoking and Sedentary Lifestyle
    • 2.5.6 Chronic Kidney Disease
  • 2.6 Disease Subtype Analysis
    • 2.6.1 Coronary Atherosclerosis
    • 2.6.2 Carotid Artery Atherosclerosis
    • 2.6.3 Peripheral Artery Atherosclerosis
    • 2.6.4 Aortic Atherosclerosis
  • 2.7 Diagnostic Pathways and Screening Trends
  • 2.8 Unmet Clinical Needs

3. Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Rising Cardiovascular Disease Burden
    • 3.1.2 Increasing Adoption of Lipid-Lowering Therapies
    • 3.1.3 Expansion of Minimally Invasive Vascular Interventions
    • 3.1.4 Growing Utilization of AI-Enabled Cardiovascular Diagnostics
  • 3.2 Market Restraints
    • 3.2.1 High Cost of Advanced Biologic Therapies
    • 3.2.2 Limited Access to Preventive Cardiovascular Screening
    • 3.2.3 Stringent Regulatory and Outcome Validation Requirements
  • 3.3 Market Opportunities
    • 3.3.1 Expansion of PCSK9 Inhibitors and Novel Lipid Therapies
    • 3.3.2 Growth in Digital Cardiovascular Monitoring
    • 3.3.3 Emerging Demand for Personalized Cardiovascular Risk Management
    • 3.3.4 Expansion Across Emerging Healthcare Markets
  • 3.4 Supply Chain Analysis
  • 3.5 Pricing and Reimbursement Trends
  • 3.6 Healthcare Infrastructure Impact

4. Commercial & Market Access

  • 4.1 Commercialization Framework
  • 4.2 Reimbursement Landscape
  • 4.3 Market Access Challenges
  • 4.4 Payer and Hospital Procurement Trends
  • 4.5 Role of Preventive Cardiology Programs
  • 4.6 Patient Adherence and Long-Term Therapy Utilization

5. Innovation & Pipeline Landscape

  • 5.1 Innovation Trends in Atherosclerosis Management
  • 5.2 Evolution of Lipid-Lowering Therapies
  • 5.3 Pipeline Landscape Overview
  • 5.4 Pipeline Candidates by Clinical Phase
    • 5.4.1 Phase I Pipeline Candidates
    • 5.4.2 Phase II Pipeline Candidates
    • 5.4.3 Phase III Pipeline Candidates
  • 5.5 Mechanism of Action Analysis
    • 5.5.1 PCSK9 Inhibitors
    • 5.5.2 siRNA-Based Lipid Therapies
    • 5.5.3 Anti-Inflammatory Cardiovascular Therapies
    • 5.5.4 CETP Inhibitors
    • 5.5.5 Gene Editing and RNA-Based Therapies
  • 5.6 Innovation in Vascular Imaging and Diagnostics
  • 5.7 AI and Predictive Cardiovascular Analytics

6. Treatment Landscape

  • 6.1 Current Standard of Care
  • 6.2 Pharmacological Treatment Landscape
    • 6.2.1 Statins
    • 6.2.2 PCSK9 Inhibitors
    • 6.2.3 Antiplatelet Agents
    • 6.2.4 Anticoagulants
    • 6.2.5 Antihypertensive Therapies
    • 6.2.6 Anti-Inflammatory Therapies
  • 6.3 Interventional Treatment Landscape
    • 6.3.1 Coronary Stenting
    • 6.3.2 Peripheral Vascular Interventions
    • 6.3.3 Carotid Artery Stenting
    • 6.3.4 Atherectomy Systems
  • 6.4 Diagnostic and Monitoring Technologies
  • 6.5 Lifestyle and Preventive Management Approaches

7. Global Atherosclerosis Market Size & Forecast

  • 7.1 Global Market Overview
  • 7.2 Historical Market Analysis
  • 7.3 Forecast Analysis (2026-2031)
  • 7.4 Market Forecast by Therapy Type
  • 7.5 Market Forecast by Drug Class
  • 7.6 Market Forecast by Indication
  • 7.7 Market Forecast by Region

8. Global Atherosclerosis Market Segmentation

  • 8.1 By Therapy Type
    • 8.1.1 Pharmacological Therapies
    • 8.1.2 Drug-Eluting Stents
    • 8.1.3 Atherectomy Devices
    • 8.1.4 Vascular Imaging Systems
    • 8.1.5 Digital Cardiovascular Monitoring Platforms
  • 8.2 By Drug Class
    • 8.2.1 Statins
    • 8.2.2 PCSK9 Inhibitors
    • 8.2.3 Antiplatelet Agents
    • 8.2.4 Anticoagulants
    • 8.2.5 Antihypertensive Agents
    • 8.2.6 Anti-Inflammatory Therapies
    • 8.2.7 Others
  • 8.3 By Indication
    • 8.3.1 Coronary Artery Disease
    • 8.3.2 Carotid Artery Disease
    • 8.3.3 Peripheral Artery Disease
    • 8.3.4 Aortic Atherosclerosis
    • 8.3.5 Chronic Total Occlusion

9. Geographical Analysis

  • 9.1 North America
    • 9.1.1 Market Size and Growth Trends
    • 9.1.2 Cardiovascular Disease Burden
    • 9.1.3 Regulatory Environment
    • 9.1.4 Competitive Intensity
    • 9.1.5 Technology Adoption Trends
  • 9.2 Europe
    • 9.2.1 Market Size and Growth Trends
    • 9.2.2 Preventive Cardiology Adoption
    • 9.2.3 Regulatory Environment
    • 9.2.4 Competitive Intensity
    • 9.2.5 Reimbursement Trends
  • 9.3 Asia-Pacific
    • 9.3.1 Market Size and Growth Trends
    • 9.3.2 Rising Metabolic Disease Burden
    • 9.3.3 Regulatory Environment
    • 9.3.4 Competitive Intensity
    • 9.3.5 Healthcare Infrastructure Expansion
  • 9.4 Latin America
    • 9.4.1 Market Size and Growth Trends
    • 9.4.2 Cardiovascular Screening Trends
    • 9.4.3 Regulatory Environment
    • 9.4.4 Competitive Intensity
    • 9.4.5 Access Challenges
  • 9.5 Middle East & Africa
    • 9.5.1 Market Size and Growth Trends
    • 9.5.2 Chronic Disease Burden
    • 9.5.3 Regulatory Environment
    • 9.5.4 Competitive Intensity
    • 9.5.5 Infrastructure Modernization

10. Key Countries Analysis

  • 10.1 United States
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 United States Regulatory Framework
    • 11.1.1 FDA Drug Approval Pathways
    • 11.1.2 Cardiovascular Device PMA and 510(k) Pathways
    • 11.1.3 Post-Market Cardiovascular Surveillance
  • 11.2 Europe Regulatory Framework
    • 11.2.1 EMA Drug Evaluation Process
    • 11.2.2 EU MDR Compliance
    • 11.2.3 Cardiovascular Outcome Monitoring
  • 11.3 Japan Regulatory Framework
    • 11.3.1 PMDA Cardiovascular Therapy Approval
    • 11.3.2 Long-Term Device Safety Assessment
  • 11.4 India Regulatory Framework
    • 11.4.1 CDSCO Drug and Device Regulation
    • 11.4.2 Pharmacovigilance Requirements
  • 11.5 China Regulatory Framework
    • 11.5.1 NMPA Approval Process
    • 11.5.2 Local Clinical Validation Requirements
  • 11.6 Global Reimbursement and HTA Trends
  • 11.7 Regulatory Impact on Innovation

12. Competitive Landscape

  • 12.1 Market Competition Overview
  • 12.2 Strategic Positioning Analysis
  • 12.3 Product Portfolio Benchmarking
  • 12.4 Partnership and Collaboration Trends
  • 12.5 Mergers and Acquisitions
  • 12.6 Innovation and Pipeline Competition
  • 12.7 AI and Digital Cardiovascular Integration Trends

13. Company Profiles

  • 13.1 Amgen
    • 13.1.1 Company Overview
    • 13.1.2 Approved Product Portfolio
      • 13.1.2.1 Repatha (evolocumab)
    • 13.1.3 Key Indications
    • 13.1.4 Pipeline Candidates and Clinical Development
    • 13.1.5 Financial Performance
    • 13.1.6 Strategic Developments
  • 13.2 Novartis
    • 13.2.1 Company Overview
    • 13.2.2 Approved Product Portfolio
      • 13.2.2.1 Leqvio (inclisiran)
    • 13.2.3 Key Indications
    • 13.2.4 Pipeline Candidates and Clinical Development
    • 13.2.5 Strategic Developments
  • 13.3 Sanofi
    • 13.3.1 Company Overview
    • 13.3.2 Approved Product Portfolio
      • 13.3.2.1 Praluent (alirocumab)
    • 13.3.3 Key Indications
    • 13.3.4 Pipeline Candidates and Clinical Development
    • 13.3.5 Strategic Developments
  • 13.4 Regeneron Pharmaceuticals
    • 13.4.1 Company Overview
    • 13.4.2 Approved Product Portfolio
      • 13.4.2.1 Praluent (alirocumab - alliance commercialization)
    • 13.4.3 Key Indications
    • 13.4.4 Pipeline Candidates and Clinical Development
    • 13.4.5 Strategic Developments
  • 13.5 Abbott Laboratories
    • 13.5.1 Company Overview
    • 13.5.2 Approved Device Portfolio
      • 13.5.2.1 XIENCE Drug-Eluting Stent System
    • 13.5.3 Key Indications
    • 13.5.4 Pipeline and Innovation Programs
    • 13.5.5 Strategic Developments
  • 13.6 Boston Scientific
    • 13.6.1 Company Overview
    • 13.6.2 Approved Device Portfolio
      • 13.6.2.1 Eluvia Drug-Eluting Vascular Stent System
      • 13.6.2.2 Ranger Drug-Coated Balloon
    • 13.6.3 Key Indications
    • 13.6.4 Pipeline and Innovation Programs
    • 13.6.5 Strategic Developments
  • 13.7 Medtronic
    • 13.7.1 Company Overview
    • 13.7.2 Approved Device Portfolio
      • 13.7.2.1 HawkOne Atherectomy System
    • 13.7.3 Key Indications
    • 13.7.4 Pipeline and Innovation Programs
    • 13.7.5 Strategic Developments
  • 13.8 Philips
    • 13.8.1 Company Overview
    • 13.8.2 Approved Imaging Portfolio
      • 13.8.2.1 IntraSight Interventional Applications
    • 13.8.3 Key Indications
    • 13.8.4 Pipeline and Innovation Programs
    • 13.8.5 Strategic Developments
  • 13.9 Terumo Corporation
    • 13.9.1 Company Overview
    • 13.9.2 Approved Device Portfolio
      • 13.9.2.1 Misago Peripheral Stent System
    • 13.9.3 Key Indications
    • 13.9.4 Pipeline and Innovation Programs
    • 13.9.5 Strategic Developments
  • 13.10 BD
    • 13.10.1 Company Overview
    • 13.10.2 Approved Device Portfolio
      • 13.10.2.1 Rotarex Atherectomy System
      • 13.10.2.2 Lutonix Drug-Coated Balloon
    • 13.10.3 Key Indications
    • 13.10.4 Pipeline and Innovation Programs
    • 13.10.5 Strategic Developments

14. Future Outlook

  • 14.1 Evolution of Preventive Cardiovascular Care
  • 14.2 Future of RNA-Based and Gene Therapies
  • 14.3 AI-Driven Cardiovascular Risk Prediction
  • 14.4 Future of Personalized Lipid Management
  • 14.5 Emerging Interventional Technologies
  • 14.6 Long-Term Strategic Industry Outlook

15. Methodology

  • 15.1 Research Methodology Overview
  • 15.2 Data Collection Framework
  • 15.3 Primary Research Methodology
  • 15.4 Secondary Research Sources
  • 15.5 Forecasting Assumptions
  • 15.6 Data Validation and Triangulation
  • 15.7 Regulatory and Clinical Trial Source Validation
  • 15.8 Limitations and Scope of Study